FROM YAHOO NEWS Latest news, live updates as 2024 election results loom TSXV - Delayed Quote ? CAD NurExone Biologic Inc. (NRX.V) Follow Compare 0.6700 -0.0100 (-1.47%) At close: November 5 at 3:59 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update TORONTO and HAIFA, Israel, Nov. 01, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicinei market, is pleased to announce, further to its press release dated September 26, 2024 (the “September 26 Release”), the closing of the final tranche of its previously announced non-brokered private placement (the “Offering”) f GlobeNewswire ? 4 days ago NRXBF NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces NRx Pharmaceuticals (NASDAQ: NRXP) will appear on the Emerging Growth Conference today in response to multiple requests and investor demand. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Jonathan Javitt, M GlobeNewswire ? 5 days ago CIA BIXT NRXBF Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now MIAMI, Oct. 30, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76th Emerging Growth Conference on October 30 & 31, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp GlobeNewswire ? 6 days ago CIA GOSS STXPF Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76th Emerging Growth Conference on October 30 & 31, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp GlobeNewswire ? 7 days ago VOXR BVAXF CIA NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA TORONTO and HAIFA, Israel, Oct. 23, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicinei market, announced its invitation to present at two conferences in exosome science this November in the United States. These invitations underscore NurExone’s rising prominence in the field as it develops innovative exosome-bas GlobeNewswire ? 13 days ago NRXBF Initiating Coverage of NRXBF By Brad Sorensen, CFA OTC:NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is a clinical stage biotech company that is developing an off-the-shelf, non-invasive and novel treatment for the reversal or reduction of paralysis following spinal cord injury using exosome-based (membrane-bound extracellular vesicles) patent-pending technology. But that one sentence description fails to Zacks Small Cap Research ? last month NRXBF NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M TORONTO and HAIFA, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicinei market, is pleased to announce a non-brokered private placement of up to 3,636,363 units (“Units”) at a price of $0.55 per Unit for aggregate gross proceeds of up to $2,000,000 (the “Offering”) and will, on acceptance of the GlobeNewswire ? last month NRXBF NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences TORONTO and HAIFA, Israel, Sept. 12, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicinei market, is pleased to announce its participation in a series of prestigious conferences this October. These events will showcase the Company’s advancements in exosome therapy, reinforce its commitment to driving innovation in GlobeNewswire ? last month NRXBF NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study TORONTO and HAIFA, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce compelling new findings that highlight the therapeutic potential of ExoPTEN for patients with spinal cord injuries. In a recent preclinical study using a spinal cord compression model, our team demonstrated that ExoPTEN has a strong ability to target and accumulate at the injury site, even when administered up to one GlobeNewswire ? last month NRXBF NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update TORONTO and HAIFA, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational results for the three and six months ended June 30, 2024, the highlights of which are included in this news release. The Company’s complete set of condensed interim consolidated financial statements for the GlobeNewswire ? 2 months ago NRXBF NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences Participation in the events in Boston and New York highlights the Company's prominence in regenerative medicine and exosome technologyTORONTO and HAIFA, Israel, Aug. 23, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce that its Chief Executive Officer, Dr. Lior Shaltiel, has been invited to speak at the upcoming Bioprocess International Conference being held from September 23 – 26 in Boston, MA. NurEx GlobeNewswire ? 2 months ago NRXBF NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process Company demonstrates reliable production from multiple biological sourcesThese manufacturing advancements provide NurExone flexibility in optimizing its exosome production method, ensuring consistency while maintaining efficiency TORONTO and HAIFA, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce significant advancements in their manufacturing process of exosomes. Exosomes, which are GlobeNewswire ? 2 months ago NRXBF NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study Study validates siRNA produced by new GMP-compliant Manufacturer and Company’s Exosomes for Drug DeliveryTORONTO and HAIFA, Israel, Aug. 09, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”) is pleased to announce new data for its ExoPTEN nanodrug, marking a significant step towards commercial-grade manufacturing. Building on the announcement of a new Good Manufacturing Practice (“GMP”) compliant Contract Research Organization GlobeNewswire ? 2 months ago NRXBF NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer TORONTO and HAIFA, Israel, Aug. 01, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is thrilled to announce an important milestone in its regenerative medicine efforts. The Company has successfully transferred the manufacturing of the small interfering RNA (“siRNA”) sequence for its flagship ExoPTEN nanodrug to a German producer with Good Manufacturing Practice (“GMP”) capabilities. GlobeNewswire ? 3 months ago NRXBF NurExone Announces Further Expansion of?ExoPTEN Patent Coverage TORONTO and HAIFA, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce that the Israel Patent Office recently issued a Notice of Allowance for an ExoPTEN patent, covering innovative Extracellular Vesicles (EVs) comprising a phosphatase and tensin homolog (“PTEN”) inhibitor and their application use. The C GlobeNewswire ? 3 months ago NRXBF Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma Minimally Invasive treatment with ExoPTEN showed functional restoration of damaged eyes to healthy levels in animalsTORONTO and HAIFA, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce the preliminary results from a small-scale controlled study exploring the use of its flagship nanodrug, ExoPTEN, for optic nerve recovery in a rat model at Sheba GlobeNewswire ? 3 months ago NRXBF Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 73rd Emerging Growth Conference on July 17 & 18 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companie GlobeNewswire ? 3 months ago CVKD GDTC CRVO Updates from NurExone: Growth Conference Presentation and Website Relaunch TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce two significant updates aimed at advancing our mission and improving stakeholder engagement. Dr. Lior Shaltiel, Chief Executive Officer of NurExone, will be presenting at the Emerging Growth Conference – Biotech Feature. This online conference is specifically tailored towards t GlobeNewswire ? 3 months ago NRXBF NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market TORONTO and HAIFA, Israel, June 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce a pre-clinical study to explore the potential of NurExone’s exosome-based therapies in regenerating damaged optic nerves. The study, initiated by renowned ophthalmologist and serial entrepreneur Prof. Michael Belkin from Tel Aviv University's Goldschleger Eye Research Institute GlobeNewswire ? 4 months ago NRXBF On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, welcomes Dr. Yona Geffen, as a consultant, to support the Company’s preclinical and clinical activities. Dr. Geffen, who currently serves as Vice President of Research and Development at Gamida Cell Ltd. (“Gamida Cell”), brings over two decades of extensive experience in leading clinical and drug dev GlobeNewswire ? 4 months ago NRXBF Performance Overview Trailing total returns as of 11/5/2024, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index Return NRX.V S&P/TSX Composite index YTD +127.12% +16.36% 1-Year +123.33% +23.02% 3-Year +55.81% +24.14%
